National Academies Press: OpenBook

Vaccines Against Malaria (1996)

Chapter: 5 Solutions for Science

« Previous: 4 Current Obstacles to Development
Suggested Citation:"5 Solutions for Science." Institute of Medicine. 1996. Vaccines Against Malaria. Washington, DC: The National Academies Press. doi: 10.17226/9027.
×

5

Solutions for Science



As outlined in Chapter 3, “The Elements for Success Are Moving into Place,” the efforts of many investigators throughout the world have laid the foundation for the development of effective malaria vaccines. Recognizing that discoveries in basic science could render any current approaches obsolete and that there is no way to predict whether such discoveries will or will not occur, the following question needs to be answered before the next steps are identified:

What is the most appropriate and efficient way to capitalize on previous work to achieve the objective of fielding effective malaria vaccines?

There was general consensus among workshop participants that the focus of the malaria vaccine effort during the next five years should be directed toward development of two separate vaccines with the following characteristics:

  • a vaccine that protects at least 90 percent of nonimmune visitors to malarious areas against the development of clinically manifest P. falciparum infection for 12 months or longer;

  • a vaccine that—when administered to children at 1, 2, and 9 months of age—reduces malaria-specific mortality in the first 6 years of life by 50 percent.

It was agreed that the first vaccine would meet the needs of the private and military markets. The second vaccine would meet minimum efficacy levels for highly endemic regions of the developing world. A single vaccine could conceivably meet both requirements, but participants acknowledged that cost considerations, as well as immunologic and epidemiologic differences in vaccine requirements, justify setting two separate goals for vaccine development.

A number of avenues need to be explored. For example, because Plasmodium is a complex, multistage microorganism, one premise holds that malaria vaccines will have to optimally induce both protective antibodies and CD4+ and CD8+ cytotoxic T-cell responses. Because we already have a validated system for testing preerythrocytic and sexual-stage vaccines in human volunteers by mosquito challenge, as well as defined protective immune

Suggested Citation:"5 Solutions for Science." Institute of Medicine. 1996. Vaccines Against Malaria. Washington, DC: The National Academies Press. doi: 10.17226/9027.
×

mechanisms and antigens, malaria vaccine development can be used as a model for testing new vaccine technologies that should be of interest to industrial partners.

Work with malaria vaccines has broadly advanced the field of vaccinology, although it has thus far failed to identify a successful vaccine against malaria itself. The first Escherichia coli–produced recombinant protein vaccine ever tested in humans was a malaria vaccine. The first synthetic peptide carrier conjugate vaccine tested in humans was also a malaria vaccine. The first assessment of DETOX (monophosphoryl lipid A and cell wall skeleton of mycobacteria) as an adjuvant for a vaccine against an infectious agent was made with malaria antigens. The first successful use of liposomes with monophosphoryl lipid A as a delivery system (adjuvant) in humans was in a malaria vaccine, and several new adjuvant formulations are now being tested in humans. The first multivalent recombinant vaccinia tested in humans was a malaria vaccine, and an early recombinant S. typhi vaccine tested in humans was a malaria vaccine.

While no one can predict what a final successful malaria vaccine will be, workshop participants generally agreed that the elements for scientific success are moving into place. What is most needed now is a focused, systematic, and multisectoral approach to vaccine development that, as a first step, identifies the scientific hurdles remaining and the funds that will be required to overcome them. In the absence of an established, coordinated strategy, however, such assessments will have little validity and will understandably lack credibility.

Suggested Citation:"5 Solutions for Science." Institute of Medicine. 1996. Vaccines Against Malaria. Washington, DC: The National Academies Press. doi: 10.17226/9027.
×
Page 17
Suggested Citation:"5 Solutions for Science." Institute of Medicine. 1996. Vaccines Against Malaria. Washington, DC: The National Academies Press. doi: 10.17226/9027.
×
Page 18
Next: 6 Solutions for Coordination »
Vaccines Against Malaria Get This Book
×
MyNAP members save 10% online.
Login or Register to save!
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!